At the heart of veterinary science lies a deep compassion for the well-being of our beloved animal companions. This is where FidoCure can make a profound impact on the quality of life of your pet battling cancer by offering hope with targeted therapy to thousands of dogs through genomic sequencing and AI-driven data analysis of cancer mutations.
We are thrilled to share with you an incredible milestone in our journey to revolutionize canine cancer treatment. Thanks to your unwavering support and dedication, we have now enrolled over 5,000 dogs in the FidoCure platform! This achievement is a testament to the trust you have placed in our innovative approach and the positive impact we are making together in the lives of dogs and their families.
Leading Animal Health Expert Dr. Fabian Kausche Joins FidoCure Advisory Board
FidoCure by the One Health Company and Stanford University Research Shared at AACR 2024
Pixelle, a 13 year old Shih Tzu, started her long cancer journey in June of 2020 when she was diagnosed with a left-sided adrenal mass after undergoing a thorough workup for vomiting, polyuria/polydipsia, and intermittent urinary incontinence. A pheochromocytoma was ruled out as a low-dose dexamethasone suppression test was consistent with Cushing’s Disease (cortisol secreting tumor).
Revolutionizing Veterinary Oncology: Precision Medicine Paves the Way for Personalized Cancer Treatment in Dogs
We would like to express our heartfelt gratitude to our veterinary community as we come to the close of the year. Together, we have made a tremendous impact by enabling precision medicine to nearly 5,000 pet dogs battling cancer.
Today we would like to share another exciting development in the field of canine oncology genetics and precision therapeutics from our manuscript "Shared Hotspot Mutations in Oncogenes Position Dogs as an Unparalleled Comparative Model for Precision Therapeutics," recently published in Scientific Reports.
